19716-60-0

Basic information

• Product Name: Oxyepiberberine
• Synonyms: Oxyepiberberine;11,12-Dihydro-8,9-dimethoxy-14H-benzo[a]-1,3-benzodioxolo[4,5-g]quinolizin-14-one;8-Oxo-epiberberine
• CAS NO: 19716-60-0
• Molecular Formula: C20H17NO5
• Molecular Weight: 351.35268
• Mol File: 19716-60-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 603.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: -1.62±0.20(Predicted)
• CAS DataBase Reference: Oxyepiberberine(CAS DataBase Reference)
• NIST Chemistry Reference: Oxyepiberberine(19716-60-0)
• EPA Substance Registry System: Oxyepiberberine(19716-60-0)

Safety Data

• Hazardous Substances Data: 19716-60-0(Hazardous Substances Data)

Usage

General Description

Oxyepiberberine is a natural alkaloid compound found in a variety of traditional Chinese medicinal herbs. It is a derivative of berberine, a well-known bioactive compound with a wide range of pharmacological properties. Oxyepiberberine has demonstrated potent antimicrobial and antitumor activities in various in vitro and in vivo studies. It has also shown potential as an anti-inflammatory agent and as a modulator of lipid metabolism. Oxyepiberberine's unique chemical structure and diverse biological activities make it an interesting target for further research and potential development as a therapeutic agent.

Upstream product

• 51665-52-2 6,7-dimethoxy-2-(5-methoxy-benzo[1,3]dioxole-4-carbonyl)-1-methylene-1,2,3,4-tetrahydro-isoquinoline 
• 1095272-10-8 N-(benzo[d][1,3]dioxol-4-ylmethyl)-2-(3,4-dimethoxyphen-yl)-ethan-1-amine 
• 1745-07-9 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 72744-54-8 5-bromo-benzo[1,3]dioxole-4-carbaldehyde 
• 7797-83-3 2H-benzo[d]1,3-dioxolane-4-carbaldehyde 
• 131543-46-9 Glyoxal 

Downstream Products

• 6873-09-2 Epiberberine 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same

The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.